JPMorgan Chase & Co. Increases BioNTech (NASDAQ:BNTX) Price Target to $121.00

BioNTech (NASDAQ:BNTX) had its price target raised by JPMorgan Chase & Co. from $116.00 to $121.00 in a research note published on Monday,Benzinga reports. JPMorgan Chase & Co. currently has a neutral rating on the stock.

A number of other analysts also recently issued reports on the company. Wells Fargo & Company set a $150.00 target price on BioNTech and gave the stock an “overweight” rating in a research note on Tuesday, August 5th. Truist Financial reaffirmed a “buy” rating and issued a $155.00 target price (up from $151.00) on shares of BioNTech in a research note on Tuesday, June 3rd. The Goldman Sachs Group began coverage on BioNTech in a research note on Thursday, May 29th. They issued a “neutral” rating and a $110.00 target price for the company. HC Wainwright reaffirmed a “buy” rating and issued a $136.00 target price on shares of BioNTech in a research note on Monday, September 8th. Finally, Wall Street Zen raised BioNTech from a “sell” rating to a “hold” rating in a research note on Saturday, June 7th. Eleven investment analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, BioNTech currently has a consensus rating of “Moderate Buy” and a consensus price target of $134.56.

BioNTech Trading Up 1.5%

Shares of BNTX stock opened at $99.75 on Monday. The stock’s fifty day moving average is $106.60 and its two-hundred day moving average is $103.25. The company has a debt-to-equity ratio of 0.01, a quick ratio of 8.48 and a current ratio of 8.61. The firm has a market capitalization of $23.98 billion, a P/E ratio of -62.34 and a beta of 1.39. BioNTech has a fifty-two week low of $81.20 and a fifty-two week high of $129.27.

BioNTech (NASDAQ:BNTX) last announced its quarterly earnings data on Monday, August 4th. The company reported ($1.60) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.41) by ($0.19). The firm had revenue of $306.46 million during the quarter, compared to analysts’ expectations of $161.26 million. BioNTech had a negative net margin of 12.20% and a negative return on equity of 1.84%. The company’s revenue for the quarter was up 102.6% on a year-over-year basis. During the same quarter in the previous year, the business posted ($3.36) EPS. BioNTech has set its FY 2025 guidance at EPS. Research analysts expect that BioNTech will post -3.88 earnings per share for the current fiscal year.

Institutional Trading of BioNTech

A number of hedge funds and other institutional investors have recently modified their holdings of BNTX. Banque Cantonale Vaudoise acquired a new stake in shares of BioNTech during the 1st quarter worth about $36,000. LRI Investments LLC increased its position in shares of BioNTech by 234.6% during the 2nd quarter. LRI Investments LLC now owns 445 shares of the company’s stock worth $47,000 after purchasing an additional 312 shares during the last quarter. Tower Research Capital LLC TRC increased its position in shares of BioNTech by 118.2% during the 2nd quarter. Tower Research Capital LLC TRC now owns 563 shares of the company’s stock worth $60,000 after purchasing an additional 305 shares during the last quarter. Hantz Financial Services Inc. increased its position in shares of BioNTech by 472.0% during the 2nd quarter. Hantz Financial Services Inc. now owns 572 shares of the company’s stock worth $61,000 after purchasing an additional 472 shares during the last quarter. Finally, Banque Transatlantique SA purchased a new position in BioNTech during the 1st quarter valued at about $80,000. 15.52% of the stock is owned by institutional investors and hedge funds.

BioNTech Company Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.